Skip to contentE
Emergent BioSolutions Inc.
E
EBSEmergent BioSolutions Inc. Q2 2021 · 10-Q
Revenue$397.50M$397.50M+0.7% vs Q2 2020 Net Income-$500.00K-$500.00KN/M vs Q2 2020 EPS Diluted-$0.01-$0.01N/M vs Q2 2020 Gross Profit$144,300,000— Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
Operating Cash Flowderived-$29,700,000N/M Free Cash Flowderived-$96,700,000N/M Margins · derivedGross margin36.3%
Operating margin1.8%−30.1 pt vs Q2 2020
Net margin-0.1%−23.6 pt vs Q2 2020
ended Jun 30, 2021 · filed Jul 30, 2021 · 30 d after period end